Skip to main navigation Skip to search Skip to main content

NCI RAS dialogue

Press/Media: Press / Media

Description

KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours

Period14 Nov 2022

Media contributions

1

Media contributions

  • TitleKRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumours
    Degree of recognitionInternational
    Media name/outletNIH National Cancer Institute
    Media typeWeb
    Country/TerritoryUnited States
    Date14/11/2022
    PersonsFebe van Maldegem
View all 1
View less